Roth Mkm Reaffirms Buy Rating for Sanuwave Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV)‘s stock had its “buy” rating restated by investment analysts at Roth Mkm in a note issued to investors on Monday,Benzinga reports. They presently have a $47.00 price target on the stock, down from their previous price target of $53.00. Roth Mkm’s price objective would suggest a potential upside of 171.83% from the stock’s previous close.

SNWV has been the subject of several other research reports. Wall Street Zen downgraded shares of Sanuwave Health from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised shares of Sanuwave Health from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $51.00.

Sanuwave Health Stock Performance

Sanuwave Health stock opened at $17.29 on Monday. The business has a 50 day moving average of $23.63 and a 200-day moving average of $29.06. Sanuwave Health has a 1 year low of $16.27 and a 1 year high of $46.58. The company has a debt-to-equity ratio of 10.08, a current ratio of 1.38 and a quick ratio of 1.05. The company has a market capitalization of $148.52 million, a P/E ratio of -108.06 and a beta of 1.32.

Sanuwave Health (NASDAQ:SNWV) last posted its earnings results on Thursday, March 26th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.14). Sanuwave Health had a negative return on equity of 141.56% and a net margin of 26.64%.The business had revenue of $13.09 million for the quarter, compared to analyst estimates of $13.23 million.

Institutional Investors Weigh In On Sanuwave Health

A number of hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC acquired a new position in Sanuwave Health in the fourth quarter valued at approximately $257,000. Praetorian PR LLC grew its position in shares of Sanuwave Health by 1,436.2% during the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock worth $7,908,000 after buying an additional 247,750 shares during the period. Bridgeway Capital Management LLC increased its stake in shares of Sanuwave Health by 76.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 39,279 shares of the company’s stock valued at $1,172,000 after acquiring an additional 17,000 shares in the last quarter. Barclays PLC increased its stake in shares of Sanuwave Health by 12.7% in the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock valued at $346,000 after acquiring an additional 1,306 shares in the last quarter. Finally, Stifel Financial Corp acquired a new position in shares of Sanuwave Health during the 4th quarter valued at $5,291,000. 42.53% of the stock is currently owned by institutional investors.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.